Sarepta Therapeutics Inc. Common Stock (DE) share price logo

Sarepta Therapeutics Inc. Common Stock (DE)

NASDAQ: SRPT

Small Cap

$17.53

+0.57

(+3.36%)

as on

Sarepta Therapeutics Inc. Common Stock (DE) Stock Performance

as on June 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $17.05
    $18.01
    downward going graph

    2.74%

    Downside

    2.74%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $10.42
    $25.32
    downward going graph

    40.59%

    Downside

    44.44%

    Upside

    downward going graph

Sarepta Therapeutics Inc. Common Stock (DE) share price movements today

Previous Close
$16.96
Open
$17.05
Volume
2.4M
Day's Low - High
$17.05 - $18.01
52 Week Low - High
$10.42 - $25.32

Sarepta Therapeutics Inc. Common Stock (DE) Historical Returns

1 Month Return
+ 5.35 %
3 Month Return
+ 5.29 %
1 Year Return
-15.6 %
3 Year Return
-86.56 %
5 Year Return
-77.91 %

Sarepta Therapeutics Inc. Common Stock (DE) Stock Fundamentals & Key Indicators

Check Sarepta Therapeutics Inc. Common Stock (DE) market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.8B

EPS (TTM)

4.8301

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

26.64%

PE Ratio (TTM)

49.16

Industry PE ratio

-3.7464601769911505

PEG Ratio

159.25

EBITDA

46.2M

Revenue (TTM)

2.2B

Profit Margin

2.98%

Return On Equity TTM

4.91%

Sarepta Therapeutics Inc. Common Stock (DE) Stock Valuation

Track how Sarepta Therapeutics Inc. Common Stock (DE) P/E has moved over time to understand its valuation trends.

Sarepta Therapeutics Inc. Common Stock (DE) in the last 5 years

  • Overview

  • Trends

Lowest (-97.89x)

December 31, 2023

Industry (-3.75x)

June 19, 2026

Today (49.16x)

June 19, 2026

Highest (170.13x)

March 31, 2024

LowHigh

Today’s Price to Earnings Ratio: 49.16x

Sarepta Therapeutics Inc. Common Stock (DE) vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Sarepta Therapeutics Inc. Common Stock (DE) with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Sarepta Therapeutics Inc. Common Stock (DE) image
Sarepta Therapeutics Inc. Common Stock (DE)
BUY$1.8B-77.91%49.162.98%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Sarepta Therapeutics Inc. Common Stock (DE) Stock including INR - Dollar returns

The Sarepta Therapeutics Inc. Common Stock (DE) stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Sarepta Therapeutics Inc. Common Stock (DE) investment value today

Current value as on today

₹91,936

Returns

-₹8,064

(-8.06%)

Returns from Sarepta Therapeutics Inc. Common Stock (DE) Stock

-₹15,599 (-15.6%)

Dollar Impact

₹7,535 (+7.54%)

Analyst Recommendation on Sarepta Therapeutics Inc. Common Stock (DE) Stock

Based on 29 analysts

BUY

82.76%

Buy

17.24%

Hold

0.00%

Sell

Based on 29 analysts, 82.76% of analysts recommend a 'BUY' rating for Sarepta Therapeutics Inc. Common Stock (DE). Average target price of $22

Sarepta Therapeutics Inc. Common Stock (DE) Share Price Target

Get share price movements and forecasts by analysts on Sarepta Therapeutics Inc. Common Stock (DE).

What analysts predicted

20.32%UPSIDE

Target Price

$22

Current Price

$17.53

Analyzed by

29 Analysts

Target

$22.00

Sarepta Therapeutics Inc. Common Stock (DE) target price $22, a slight upside of 20.32% compared to current price of $17.53. According to 29 analysts rating.

Indian Investors' Interest in Sarepta Therapeutics Inc. Common Stock (DE) Stock

Investment in Sarepta Therapeutics Inc. Common Stock (DE) Shares on INDmoney has grown by 44.31% in the last 30 days, indicating increased investment activity.

Time period: to

Change:44.31% versus previous 30 day period

Search interest for Sarepta Therapeutics Inc. Common Stock (DE) Stock has increased by 8% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:8% versus previous 30 day period

Sarepta Therapeutics Inc. Common Stock (DE) Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
396
413
362
467
658
744
611
399
442
730
Gross Profit
352
362
318
375
526
607
458
248
44
611
Operating Income
24
34
0
22
161
-300
115
-103
-411
358
EBITDA
56
54
27
48
186
-369
169
-168
-252
375
Interest Expense
5
4
4
4
4
4
5
7
7
21
Depreciation
11
8
8
9
10
9
10
18
5
10
Income Before Tax
40
41
13
34
171
-383
153
-194
-278
343
Income Tax Expense
-5
5
7
0
12
63
-43
-14
4
12
Net Income
45
36
6
33
159
-447
196
-179
-282
330
Net Profit Margin
11.51%
8.74%
1.78%
7.19%
24.16%
-60.08%
32.22%
-45.06%
-63.86%
45.29%

Sarepta Therapeutics Inc. Common Stock (DE) Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
5
154
301
380
540
701
933
1,243
1,901
2,198
Gross Profit
5
147
266
324
476
604
793
1,092
1,582
1,316
Operating Income
-266
-171
-343
-705
-564
-459
-536
-267
218
-657
EBITDA
-261
-34
-316
-658
-453
-317
-594
-453
316
-647
Interest Expense
0
5
33
30
59
63
53
22
18
9
Depreciation
-
8
12
30
26
38
41
43
37
44
Income Before Tax
-267
-48
-362
-713
-553
-418
-689
-520
260
-702
Income Tax Expense
-7
2
0
1
1
0
13
15
25
11
Net Income
-267
-50
-361
-715
-554
-418
-703
-535
235
-713
Net Profit Margin
-4930.18%
-32.79%
-120.22%
-187.77%
-102.60%
-59.66%
-75.40%
-43.11%
12.37%
-32.45%

Sarepta Therapeutics Inc. Common Stock (DE) Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
36
6
33
159
-447
196
-179
-282
330
Operating Cash Flow
-242
14
-70
92
-583
261
-14
131
-202
Investing Cash Flow
218
-98
-128
764
-291
32
232
96
-134
Financing Cash Flow
22
39
13
48
12
-23
-117
-39
0
Change in Cash
-1
-43
-185
905
-862
269
100
188
-336

Sarepta Therapeutics Inc. Common Stock (DE) Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-50
-361
-715
-554
-418
-703
-535
235
-713
Operating Cash Flow
-231
-388
-456
107
-443
-325
-500
-205
-205
Investing Cash Flow
-178
-370
286
-121
495
-1,046
-165
755
69
Financing Cash Flow
888
530
642
682
561
232
125
124
-168
Change in Cash
477
-228
472
668
613
-1,139
-541
674
-304

Global Institutional Holdings in Sarepta Therapeutics Inc. Common Stock (DE)

Funds
Holdings
D. E. Shaw & Co LP
1.46%
BlackRock Inc
13.98%
State Street Corp
6.26%
AQR Capital Management LLC
6.09%
Morgan Stanley - Brokerage Accounts
2.46%
See all

Sarepta Therapeutics Inc. Common Stock (DE) News & Key Events

  • img

    Today's Timeline - 08 June

    Mon, 09:30 PM

    -

    Sarepta upgraded to Zacks Rank #2 (Buy) due to positive earnings outlook and rising estimates.

    Tue, 02:49 AM

    -

    Sarepta files $341.99 million shelf registration for equity plans, signaling focus on growth and profitability.

Insights on Sarepta Therapeutics Inc. Common Stock (DE)

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -282.84M → 330.95M (in $), with an average increase of 185.5% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, SRPT stock has moved up by 14.5%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 399.35M → 730.80M (in $), with an average increase of 24.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 32.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sarepta Therapeutics, Inc. Common Stock DE has experienced a drawdown of -86.7%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 64.8%

About Sarepta Therapeutics Inc. Common Stock (DE)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
OrganisationSarepta Therapeutics Inc. Common Stock (DE)
Headquarters215 First Street, Cambridge, MA, United States, 02142
IndustryBiotechnology
CEOMr. Douglas S. Ingram Esq., J.D.
E-voting on sharesClick here to vote

Key Management of Sarepta Therapeutics Inc. Common Stock (DE)

Name

Title

Mr. Ian Michael Estepan

President & COO

Rachael Potter Ph.D.

Chief Scientific Officer

Tamara Thornton

Director of Finance, Treasury & Investor Relations

Ms. Alison Nasisi

Executive VP & Chief People Officer

Patrick Moss Pharm.D.

Executive VP & Chief Commercial Officer

Mr. Douglas S. Ingram Esq., J.D.

CEO & Director

Mr. Ryan H. Wong

Executive VP & CFO

Ms. Cristin L. Rothfuss J.D.

Executive VP, General Counsel & Company Secretary

Dr. Louise R. Rodino-Klapac Ph.D.

President of Research & Development and Technical Operations

Dr. Diane L. Berry Ph.D.

Executive VP and Chief of Global Policy & Advocacy Officer

FAQs

What is Sarepta Therapeutics Inc. Common Stock (DE) share price today?

Sarepta Therapeutics Inc. Common Stock (DE) share price today is $17.53 as on at the close of the market. Sarepta Therapeutics Inc. Common Stock (DE) share today touched a day high of $18.01 and a low of $17.05.

What is the 52 week high and 52 week low for Sarepta Therapeutics Inc. Common Stock (DE) share?

Sarepta Therapeutics Inc. Common Stock (DE) share touched a 52 week high of $25.32 on and a 52 week low of $10.42 on . Sarepta Therapeutics Inc. Common Stock (DE) stock price today i.e. is closed at $17.53,which is 30.77% down from its 52 week high and 68.31% up from its 52 week low.

What is Sarepta Therapeutics Inc. Common Stock (DE)'s market capitalisation today?

Sarepta Therapeutics Inc. Common Stock (DE) market capitalisation is $0.00T as on .

How to invest in Sarepta Therapeutics Inc. Common Stock (DE) Stock (SRPT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Sarepta Therapeutics Inc. Common Stock (DE) on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sarepta Therapeutics Inc. Common Stock (DE) Shares that will get you 0.0856 shares as per Sarepta Therapeutics Inc. Common Stock (DE) share price of $17.53 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Sarepta Therapeutics Inc. Common Stock (DE) Stock (SRPT) from India?

Indian investors can start investing in Sarepta Therapeutics Inc. Common Stock (DE) (SRPT) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Sarepta Therapeutics Inc. Common Stock (DE) stock (as per the Rupee-Dollar exchange rate as on ). Based on Sarepta Therapeutics Inc. Common Stock (DE) share’s latest price of $17.53 as on June 19, 2026 at 8:46 am IST, you will get 0.5705 shares of Sarepta Therapeutics Inc. Common Stock (DE). Learn more about fractional shares .

What are the returns that Sarepta Therapeutics Inc. Common Stock (DE) has given to Indian investors in the last 5 years?

Sarepta Therapeutics Inc. Common Stock (DE) stock has given -77.91% share price returns and 27.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?